跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MVABEA SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
MVABEA SUSPENSION INYECTABLE
Approved
STANDARD
MVABEA SUSPENSION INYECTABLE
Janssen-Cilag International N.V
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
May 25, 2021
Approval ID
55348d8a7bd84f31
Company
Janssen-Cilag International N.V
Type
Standard
Approval Details
Approval Id
55348d8a7bd84f31
Drug Cima Aemps Name
MVABEA SUSPENSION INYECTABLE
Register Number
1201445001
Holder Company Name
Janssen-Cilag International N.V
Marketing Company Name
Janssen Cilag S.A.
Holder Company Detail Path
/organization/janssen-cilag-international-nv
Authorization Date
2021-05-25
Dosage Form
SUSPENSIÓN INYECTABLE
Dose
0,5 ml
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Janssen-Cilag International N.V
Company Detail Path
/organization/janssen-cilag-international-nv
Company Information
Pharmaceutical Company Name
Janssen-Cilag International NV
Country Name
Belgium
Active Ingredients
VACUNA DE VECTOR VACCINIA ANKARA MODIFICADO, MULTIVALENTE, VIVA, RECOMBINANTE, NO REPLICATIVO EN CELULAS HUMANAS, QUE EXPRESA LAS GLICOPROTEINAS (GP) DE LOS VIRUS DEL EBOLA MAYINGA, SUDAN GULU, MARBURGO Y MUSOKE Y NUCLOPROTEINA DEL VIRUS TAI FOREST
0,7x10e8 unidades infecciosas (Inf.U)
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
May 25, 2021
Approval ID
55348d8a7bd84f31
Type
Standard
Back to CIMA-AEMPS Approvals